| Literature DB >> 24018211 |
L Puig1, J M Carrascosa, G Carretero, P de la Cueva, R F Lafuente-Urrez, I Belinchón, M Sánchez-Regaña, M García-Bustínduy, M Ribera, M Alsina, C Ferrándiz, E Fonseca, V García-Patos, E Herrera, J L López-Estebaranz, S E Marrón, J C Moreno, J Notario, R Rivera, C Rodriguez-Cerdeira, A Romero, R Ruiz-Villaverde, R Taberner, D Vidal.
Abstract
Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic.Entities:
Keywords: Adalimumab; Biologic agents; Biologic therapy; Biológicos; Clinical practice guidelines; Etanercept; Guía; Infliximab; Psoriasis; Terapia biológica; Tratamiento; Treatment; Ustekinumab
Mesh:
Substances:
Year: 2013 PMID: 24018211 DOI: 10.1016/j.adengl.2013.04.013
Source DB: PubMed Journal: Actas Dermosifiliogr ISSN: 0001-7310